JPRN-UMIN000026002招募中未知
A phase II study of the dose reduction and shortening of duration of immunosuppressant after HLA-haploidentical transplantation with post-transplantation cyclophosphamide following reduced-intensity conditioning - JSCT-Haplo17 RIC
JSCT0 个研究点目标入组 55 人开始时间: 2017年4月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who are positive for HBs antigen, HCV antibody, or HIV antibody. 2. Patients with active other malignancies. 3. Patients with active infectious disease. 4. Women who are pregnant, of childbearing potential, or lactating. 5. Patients who experienced serious hypersensitivity or anaphylaxis to cyclophosphamide, fludarabine, tacrolimus, mycophenolate mofetil. 6. Positive anti-donor HLA antibody. 7. Patients who need chemotherapy within 13 days before transplantation. 8. Patients whose body mass index is >=30. 9. Patients who are not eligible for this study at the discretion of the investigator.
研究者
相似试验
招募中
不适用
A phase II study of the dose reduction and shortening of duration of immunosuppressant after HLA-haploloidentical transplantation with post-transplantation cyclophosphamide following myeloablative conditioninghematologic malignanciesJPRN-UMIN000026001JSCT42
进行中（未招募）
1 期
A Study, in which patients with advanced hepatocellular carcinoma (HCC) and preserved liver function are treated with a reduced starting dose ofcabozantinib, followed by an increase of dose, after treatment failure of one previous therapyAdvanced stage hepatocellular carcinoma (HCC) patients with preserved liver function in second line therapyEUCTR2020-000775-20-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest40
招募中
不适用
Study of efficacy and safety of dose reduction in the oral cavity by target volume definition using PET/CT for intensity-modulated radiation therapy of head and neck cancersHead-and-neck cancerJPRN-UMIN000033007Juntendo University,Graduate School of Medicine,Department of Radiation Oncology10
进行中（未招募）
2 期
Shortened Course Adjuvant Radiotherapy Following TORSHPV-Associated Oropharyngeal Squamous Cell CarcinomaNCT05714657Abramson Cancer Center at Penn Medicine104
进行中（未招募）
不适用
ow doses of Rituximab in Graves orbitopathyActive moderate to severe Graves OrbitopathyMedDRA version: 14.1Level: PTClassification code 10060742Term: Endocrine ophthalmopathySystem Organ Class: 10015919 - Eye disordersEUCTR2012-001980-53-ITFONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO10